Quest Diagnostics Secures Vital CDC Contracts
Quest Diagnostics, a leading provider of diagnostic information services, has recently been awarded significant contracts by the U.S. Centers for Disease Control and Prevention (CDC). These contracts are vital for enhancing the testing capabilities and laboratory readiness for two emerging infectious diseases in the Americas.
Enhancing Public Health Preparedness
These agreements aim to fortify the nation’s preparedness for avian influenza and Oropouche viruses. By ensuring that a national commercial laboratory can quickly support public health laboratories during infectious disease outbreaks, Quest Diagnostics plays an essential role in safeguarding public health. The funding provided through these contracts is designed to maintain necessary testing readiness, including ensuring a steady supply of essential equipment and reagents.
Avian Influenza Testing Initiative
A key aspect of this initiative is Quest's commitment to launching a new molecular laboratory test for avian influenza A H5. This advanced multi-target diagnostic test is meant for individuals suspected of being infected with the influenza A H5 virus and will soon be available via prescription from healthcare providers. The company’s state-of-the-art laboratory, located in California, has been pivotal in developing this crucial test.
Collaboration with CDC for Pandemic Response
With CDC's support, Quest Diagnostics developed this innovative testing solution as part of its proactive approach to pandemic response. This test specifically targets the influenza A H5 virus, including the A(H5N1) strain, but it does not detect seasonal influenza A subtypes or influenza B, thereby allowing for a focused approach on possible avian flu infections.
Increased Access and Testing Capacity
Before the introduction of Quest's new testing capabilities, individuals who tested positive for influenza A through commercial laboratories had to route their specimens to state health labs or CDC for further testing to confirm avian influenza. With this new test, healthcare providers can directly order testing from a national commercial laboratory, greatly enhancing access and testing capacity. This adjustment is particularly critical when symptoms suggest exposure to the avian influenza virus.
Expert Insights on Emerging Diseases
Dr. Yuri Fesko, Senior Vice President and Chief Medical Officer at Quest Diagnostics, remarked, "Managing emerging diseases like avian influenza necessitates tight collaboration between the commercial laboratory sector and public health authorities for effective monitoring and swift response capabilities." The partnerships fostered through these contracts allow Quest to maintain necessary infrastructure to swiftly address potential health emergencies.
The State of Avian Influenza and Oropouche Virus
The avian influenza A(H5N1) virus continues to be a global concern, affecting wild birds and leading to outbreaks among U.S. poultry and dairy cows, with occasional human infections primarily among farm workers. Currently, the public health risk remains low, but CDC is closely monitoring developments in this area.
In addition to the avian flu, CDC has also contracted Quest to develop a diagnostic test for the Oropouche virus, which is transmitted to humans via infected biting midges and certain mosquito species. While the threat level for both viruses is considered low at this time, these preemptive efforts by CDC ensure that readiness measures are in place for any future surge in cases.
About Quest Diagnostics
Quest Diagnostics plays a critical role in the healthcare ecosystem by providing diagnostic insights to empower individuals, physicians, and organizations toward improved health outcomes. With a vast database of clinical lab results, Quest's insights open new possibilities for disease identification and treatment, strengthening the overall management of healthcare. Serving a significant proportion of the U.S. population, Quest Diagnostics leverages the expertise of over 50,000 employees who are committed to making a difference in people's lives.
Frequently Asked Questions
What are the new contracts Quest Diagnostics received?
Quest Diagnostics secured contracts from the CDC to enhance testing capabilities for avian influenza and Oropouche viruses.
How will the new tests improve public health preparedness?
The tests will quicken the response to potential outbreaks, allowing for faster diagnosis and treatment.
Where is the testing lab located?
The advanced laboratory responsible for the new avian influenza test is based in California.
What does the new avian influenza test entail?
This test is a molecular diagnostic designed for rapid detection of the avian influenza A H5 virus in symptomatic individuals.
Who is impacted by avian influenza outbreaks?
Avian influenza primarily affects wild birds, poultry, and humans who have close contact with infected animals, mainly farm workers.
